Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
En ja hoor eindelijk beet. Valbiotis heeft een grote partner! Nestlé Andere Franse biotech aandelen deden het in 2019 en de eerste maand van 2020 al: enorm stijgen. Morgen is het de beurt aan Valbiotis dat in 2017 voor 10 euro naar de beurs ging. Had oktober 2019 geld nodig, maar staat er door deze deal prima voor.www.businesswire.com/news/home/202002... VALBIOTIS Announces a Global Strategic Partnership With NESTLÉ HEALTH SCIENCE For the Development and Commercialization of TOTUM-63, a Plant-derived Active Substance With Clinically Demonstrated Metabolic Health Benefits on Prediabetics Nestlé Health Science’s global reach and metabolic diseases focus expected to support TOTUM-63 development and global commercialization; Strategic partnership secures funding for the latest clinical development phase until the obtention of health claims from American and European Authorities; Deal is structured around an upfront payment of CHF 5 million, development & sales milestone payments up to a maximum of CHF 66 million and tiered royalties on net sales; Agreement also includes TOTUM-63 supply to Nestlé Health Science representing an additional source of revenue. February 05, 2020 12:30 PM Eastern Standard Time LA ROCHELLE, France--(BUSINESS WIRE)--Regulatory News: “The research and development that VALBIOTIS is doing is very promising. We look forward to working together to realize the commercialization of TOTUM-63, an innovative approach to reducing the risk of Type 2 Diabetes.” VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / PEA/SME eligible ), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces the signature of a global long-term strategic partnership with Nestlé Health Science for the development and commercialization of TOTUM-63, an innovative and patented combination of 5 plant extracts specifically designed to reduce the risk of developing Type 2 Diabetes on prediabetics. Sébastien PELTIER, CEO of VALBIOTIS states: “Nestlé Health Science is an ideal strategic partner for VALBIOTIS. Its global reach, strategic intent to develop science-based nutritional health solutions and focus on fighting metabolic disorders like diabetes will be instrumental to TOTUM-63's worldwide commercialization success. We are excited about the opportunity that this deal brings to VALBIOTIS and to the many millions of people around the world at risk of becoming Type 2 diabetics. This transformational deal arrives just five years after the creation of VALBIOTIS and is a recognition of the hard work, commitment and vision of our team”. Hans-Juergen WOERLE, Chief Science & Medical Officer of Nestlé Health Science, said, "The research and development that VALBIOTIS is doing is very promising. We look forward to working together to realize the commercialization of TOTUM-63, an innovative approach to reducing the risk of Type 2 Diabetes." Under the terms of the agreement, VALBIOTIS grants Nestlé Health Science exclusive and global commercial rights to use TOTUM-63 in the prediabetes and Type 2 Diabetes market. The agreement defines a number of priority markets for a global commercialization. In exchange for these rights, Nestlé Health Science commits to an upfront payment of CHF 5 million, development & sales milestone payments up to a maximum of CHF 66 million, and tiered royalties on net sales. The partnership will support VALBIOTIS's work in a number of ways, including funding the latest clinical development phase until health claims are obtained by the appropriate authorities in the United States and Europe. The financial terms of this agreement significantly extend VALBIOTIS’s cash runway. The commercialization of TOTUM-63 may take place before obtaining health claims. Agreement also includes TOTUM-63 supply to Nestlé Health Science, representing an additional source of revenue for VALBIOTIS. As part of the agreement, a joint steering committee comprised of representatives of both companies will oversee clinical development, regulatory matters, supply and commercialization. Beyond this strategic partnership on TOTUM-63 to reduce the risk of developing Type 2 Diabetes, VALBIOTIS intends to pursue its other R&D programs: TOTUM-070, to reduce blood LDL-cholesterol, an independent risk factor for cardiovascular diseases, TOTUM-8541, to reduce blood pressure, an independent risk factor for cardiovascular diseases and TOTUM-4481, in fatty liver disease, a condition with high risk of developing NASH. The Company will provide further details on its pipeline in a subsequent communications. Resumption of trading of VALBIOTIS shares on Euronext Growth will take place on February 6, 2020 at 9:00 am. ABOUT TOTUM-63 TOTUM-63 is a unique and patented combination of 5 plant extracts, with high potential to target the physiopathological mechanisms of Type 2 Diabetes. TOTUM-63 has already been proven safe and effective in healthy human volunteers during a Phase I/II clinical study. The results of the international randomized, placebo-controlled Phase II study showed that TOTUM-63 reduced fasting and 2-hour blood sugar levels, two risk factors for Type 2 Diabetes, in prediabetics compared to placebo. In these subjects, who also had abdominal obesity, TOTUM-63 significantly reduced body weight and waist circumference. TOTUM-63 benefits from intellectual property granted in the main markets worldwide: Europe (covering 39 countries), the United States, Russia and national phases are underway in more than 20 countries including China, Japan, Brazil, Australia. The ability to produce TOTUM-63 industrially, in compliance to North American and European standards, has been validated. TOTUM-63 already has marketing authorizations related to its status in Europe.
ABOUT NESTLE HEALTH SCIENCE Nestlé Health Science (NHSc), a wholly-owned subsidiary of Nestlé, is a globally recognized leader in the field of nutritional science. At NHSc we are committed to empowering healthier lives through nutrition for consumers, patients and their healthcare partners. We offer an extensive consumer health portfolio of industry-leading medical nutrition, consumer and VMS brands that are science-based solutions covering all facets of health from prevention, to maintenance, all the way through to treatment. Headquartered in Switzerland, NHSc employs over 5’000 people around the world, who are committed to making a difference in people’s lives, for a healthier today and tomorrow. For more information, please visit: www.nestlehealthscience.com. ABOUT VALBIOTIS VALBIOTIS is a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases in response to unmet medical needs. VALBIOTIS has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of nutritional health solutions designed to reduce the risk of major metabolic diseases, based on a multi-target approach and made possible by the use of plant-based ingredients. Its products are intended to be licensed to players in the health world. VALBIOTIS was founded in La Rochelle in early 2014 and has formed numerous partnerships with top academic centers. The Company has established three sites in France – Périgny, La Rochelle (17) and Riom (63). VALBIOTIS is a member of the "BPI Excellence" network and received the "Innovative Company" status accorded by BPI France. Valbiotis has also been awarded "Young Innovative Company" status and has received major financial support from the European Union for its research programs by obtaining support from the European Regional Development Fund (ERDF). VALBIOTIS is a PEA-SME eligible company. For more information about VALBIOTIS, please visit: www.valbiotis.com ============================ Een dag van ruim 100% zou mij niets verbazen. Succes, poil
En gelijk een keurig nette presentatie op de site van Valbiotiswww.valbiotis.com/en/documents/ Succes en fijne avond, poil
@poil-1; heb je wel eens naar PARX gekeken. Ik weet dat dit niet onder dit draadje geplaatst moet worden, maar weet even niet hoe ik het je op een andere manier moet laten weten. Straks (9u) webcast over hun technieken, inloggen via hun website.
Dit was een prima dag. Proost, poil
enig idee waar de koers naartoe kan gaan binnen M termijn ?
As part of a global partnership with Nestlé Health Science, VALBIOTIS initiates the pivotal late stage development phase of TOTUM-63, a plant-derived active substance with clinically demonstrated metabolic health benefits in people with prediabetes 1 This last pivotal trial (REVERSE-IT), has been designed jointly with Nestlé Health Science’s teams and will be entirely funded by the partnership agreement; This international trial will include 600 participants and should be launched before mid-2020; Its first objective is to confirm the positive results of the Phase II clinical trial on fasting blood sugar levels, a well-established risk factor for developing Type 2 Diabetes, to obtain strong health claims; The trial aims to include a broad population with altered glucose metabolism, spanning from elevated fasting glucose to early (yet untreated) Type 2 Diabetes. La Rochelle, 2 April 2020 (7:35 AM CEST) VALBIOTIS (FR0013254851 – ALVAL / PEA/ SME eligible), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces today, that as part of its global partnership with Nestlé Health Science, it is launching the pivotal late stage development phase of TOTUM-63, a plant-derived active substance with clinically demonstrated metabolic health benefits on people with prediabetes. This last phase of the clinical development was co-designed with Nestlé Health Science’s medical and regulatory teams and consists of one pivotal Phase II/III clinical study, called REVERSE-IT. This clinical trial will include people with prediabetes and with early stage untreated Type 2 Diabetes. It will pursue two main strategic objectives: - Replicate the previous Phase II positive result on fasting blood sugar levels, a well- established risk factor for developing Type 2 Diabetes; - Extend the evaluation of TOTUM-63 to patients with early stage untreated Type 2 Diabetes, to enlarge the final target population. The launch of the REVERSE-IT trial is planned for the first half of 2020. In order to rapidly complete the recruitment, the trial will be led in more than 30 international clinical centers. It will be entirely funded by the partnership signed in February 2020 with Nestlé Health Science.
“The REVERSE-IT study results from the combined expertise of VALBIOTIS and Nestlé Health Science. We have strong ambitions for this last regulatory clinical phase, that are based on the very good results we obtained in the previous Phase II clinical trial. Considering the resources we mobilize, we can reasonably expect the topline data to be released before mid-2022. We feel enthusiastic for this final step of our innovative R&D process and we are confident in the fact that it will get TOTUM-63 to wide and successful commercialization, which may take place before obtaining health claims.” “The scope and conditions of this clinical trial are significant: it is being led in 30 international clinical settings with 600 participants. The thoroughness of this trial will provide results that are extremely useful in demonstrating a safe and effective opportunity to help patients who have prediabetes and Type 2 Diabetes.” The REVERSE-IT trial will be randomized and placebo-controlled, with the same primary objective (reduction in fasting glycemia), the same duration of supplementation (6 months) and the same tested dose (5g/day) and regimen (three times per day) than the previous Phase II study, which positive results were published in 2019 (Press releases, 3rd July 2019 and 2nd September 2019). The study population will include 600 subjects with abnormally elevated fasting blood glucose (dysglycemia) and abdominal obesity, two frequently associated conditions. The number of subjects included will guarantee the robustness of this pivotal trial. Led in a wider population, this trial will also pursue larger clinical objectives, with a three-arm design. The regimen of three doses per day, for a total daily dose of 5g, will be tested against placebo (200 subjects receiving TOTUM-63 in one arm and 200 subjects receiving a placebo in the second arm). The primary criterion is the reduction in fasting blood glucose against placebo, with this three doses per day regimen. A third open label arm will test a regimen of two doses per day, for the same total daily dose of 5g, on 200 subjects. The trial will evaluate several other metabolic criteria of high interest for people with prediabetes or early stage untreated Type 2 Diabetes. The partnership with Nestlé Health Science also plans an adjunct clinical study to obtain exploratory data on TOTUM-63 mode of action in humans. VALBIOTIS will provide details on its other products in a subsequent communication. Murielle CAZAUBIEL, Head of Development & Medical Affairs of VALBIOTIS Hans-Juergen WOERLE, Chief Scientific & Medical Officer of Nestlé Health Science Groet,,poil
Prima nieuws. Er worden (zelfs in deze tijden) stappen gezet die dit bedrijf weer terug gaat brengen waar het een paar jaar geleden begon. Mijn voorlopige koersdoel 10 euro. Succes, poil
Valbiotis: Invest Securities verhoogt haar richtprijs CERCLE FINANCE • 06/09/2020 om 09:37 (CercleFinance.com) - Invest Securities verhoogt zijn richtprijs naar 13E (tegen 11E) en herhaalt zijn advies over het kopen van waarde. Het analysebureau is van mening dat de huidige waardering (29 ME), in perspectief te plaatsen met de met Nestlé ondertekende overeenkomst (67 ME), het potentieel van de pijplijn niet nauwkeurig weergeeft. 'We werken ons model op verschillende punten bij: (i) we passen onze schattingen voor Totum-63 aan na de ondertekening van de commerciële overeenkomst met Nestlé Health Science in de prediabetes die de strategie geloofwaardiger heeft gemaakt, (ii) we integreren Totum-854, ontwikkeld in de vermindering van cardiovasculair risico en (iii) we herzien onze schattingen voor Totum-070 bij hypercholesterolemie en voor Totum-448 bij NASH-risico ', zegt Invest Securities. Gisteren 15% in de plus. Vandaag Valbiotis SAS 4,50 0,20 4,65 % 09:39:21 Groet, poil
TO READ Open boek]#ADA2020 starts today and we will be presenting clinical results of TOTUM-63 for the prevention of type 2 diabetes. The abstract is now available on the @AmDiabetesAssn Pijl naar rechts bit.ly/3hnAnGc #ADAGoesVirtual Ter info, poil
www.businesswire.com/news/home/202006... VALBIOTIS geselecteerd tijdens de 80e wetenschappelijke sessies van de American Diabetes Association om klinische fase II-resultaten van TOTUM-63 te presenteren bij prediabetes Deze publicatie, uitgebracht tijdens het grootste diabetescongres ter wereld, biedt een ondubbelzinnige wetenschappelijke onderschrijving van de resultaten. TOTUM-63, een op planten gebaseerde werkzame stof, toont met Europese multicenter Fase II-studie van 51 prediabetische personen de impact ervan op de nuchtere bloedglucosespiegels aan, een bekende risicofactor voor diabetes type 2.De beschikbaarheid ervan in het kader van een wereldwijde overeenkomst met Nestlé Health Science zou voor professionals in de gezondheidszorg de eerste mogelijkheid kunnen zijn om hun prediabetische patiënten te helpen met een klinisch bewezen en plantaardig product. June 12, 2020 03:39 AM Eastern Daylight Time LA ROCHELLE, Frankrijk--(BUSINESS WIRE)--VALBIOTIS (Parijs: ALVAL) (FR0013254851 – ALVAL / PEA / SME komt in aanmerking), een onderzoeks- en ontwikkelingsbedrijf dat zich inzet voor wetenschappelijke innovatie voor het voorkomen en bestrijden van metabole ziekten, kondigt aan dat de belangrijkste resultaten van zijn Tijdens de 80e wetenschappelijke sessies van de American Diabetes Association (ADA) worden internationale fase II klinische onderzoeken gepresenteerd die de metabole voordelen van TOTUM-63 bij prediabetische patiënten aantonen. Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal, die als enige rechtsgeldig is. Ter info, poil
Koers deze dagen uit gebroken en ook vandaag met flink volume. Nog meer geïnteresseerden welke dit aandeel volgen? Wat zijn jullie verwachtingen tm december. Koersdoel liegt er niet om bij huidige koers..
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
865,36
+0,00%
EUR/USD
1,0619
-0,23%
FTSE 100
7.877,05
+0,37%
Germany40^
17.751,90
-0,48%
Gold spot
2.400,91
+0,91%
NY-Nasdaq Composite
15.601,50
-0,52%
Stijgers
Dalers